The Centre for Addiction and Mental Health in Toronto as well as other hospitals are encountering extreme shortages of two very important and potent injectable pharmaceutical products. The product is Haloperidol LA 50 and 100 mg/ml intramuscular injection used as an antipsychotic agent. Possible availability for the latter is sometime in December; the former has no expected delivery date. In addition, the anxiety reducing Lorazepam 4 mg/ml, 1 ml vials is unavailable until sometime in December as well. Pharmacist-led discussions and communication is occurring with clinicians to determine best possible alternatives for patients, including those that have been stabilized on the long acting antipsychotic, Haloperidol.
Wayne Marigold, Director, Pharmaceutical Services
Centre for Addiction and Mental Health (CAMH)